ECSP21051067A - Amidas de pirrolidina III sustituidas - Google Patents

Amidas de pirrolidina III sustituidas

Info

Publication number
ECSP21051067A
ECSP21051067A ECSENADI202151067A ECDI202151067A ECSP21051067A EC SP21051067 A ECSP21051067 A EC SP21051067A EC SENADI202151067 A ECSENADI202151067 A EC SENADI202151067A EC DI202151067 A ECDI202151067 A EC DI202151067A EC SP21051067 A ECSP21051067 A EC SP21051067A
Authority
EC
Ecuador
Prior art keywords
amides
substituted pyrrolidine
iii
pyrrolidine iii
glucocorticoid receptor
Prior art date
Application number
ECSENADI202151067A
Other languages
English (en)
Inventor
Philipp Barbie
Stephanie Hennen
Sebastian Krüger
Daniela Friebe
Florian Jakob
Jo Alen
Original Assignee
Gruenenthal Gmbh [De/De]
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh [De/De] filed Critical Gruenenthal Gmbh [De/De]
Publication of ECSP21051067A publication Critical patent/ECSP21051067A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de conformidad con la fórmula general (I), que actúan como moduladores del receptor de glucocorticoides y que se pueden utilizar en el tratamiento y/o la profilaxis de trastornos que son mediados, al menos parcialmente, por el receptor de glucocorticoides.
ECSENADI202151067A 2019-01-11 2021-07-09 Amidas de pirrolidina III sustituidas ECSP21051067A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19151406 2019-01-11
EP19152282 2019-01-17
EP19181203 2019-06-19

Publications (1)

Publication Number Publication Date
ECSP21051067A true ECSP21051067A (es) 2021-12-30

Family

ID=69165383

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202151067A ECSP21051067A (es) 2019-01-11 2021-07-09 Amidas de pirrolidina III sustituidas

Country Status (16)

Country Link
US (2) US20200223840A1 (es)
EP (1) EP3908581A1 (es)
JP (1) JP7446316B2 (es)
KR (1) KR20210114972A (es)
CN (1) CN113382990A (es)
AU (1) AU2020207591A1 (es)
BR (1) BR112021013557A2 (es)
CA (1) CA3125929A1 (es)
CL (1) CL2021001823A1 (es)
CO (1) CO2021008998A2 (es)
EC (1) ECSP21051067A (es)
IL (1) IL284642A (es)
MX (1) MX2021008364A (es)
PE (1) PE20211733A1 (es)
TW (1) TWI827785B (es)
WO (1) WO2020144375A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL275333B2 (en) 2017-12-15 2023-09-01 Praxis Biotech LLC Inhibitors of fibroblast activation protein
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815361A (en) 2005-10-20 2008-04-01 Astrazeneca Ab Chemical compounds
WO2007114763A1 (en) * 2006-03-31 2007-10-11 Astrazeneca Ab Sulphonamide derivates as modulators of the glucocorticoid receptor
US8178573B2 (en) * 2006-04-20 2012-05-15 Glaxo Group Limited Compounds
GB0620385D0 (en) 2006-10-13 2006-11-22 Glaxo Group Ltd Novel compounds
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
JP2009084273A (ja) 2007-09-13 2009-04-23 Santen Pharmaceut Co Ltd １，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体からなるグルココルチコイド受容体アゴニスト
TWI445705B (zh) * 2008-05-20 2014-07-21 Astrazeneca Ab 經苯基及苯并二基取代之吲唑衍生物
TW201416348A (zh) * 2012-08-29 2014-05-01 Gruenenthal Chemie 以氟甲基取代之吡咯甲醯胺
TN2017000096A1 (en) 2014-09-26 2018-07-04 Astrazeneca Ab 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators.
KR20180043329A (ko) 2015-08-25 2018-04-27 산텐 세이야꾸 가부시키가이샤 [4-(1,3,3-트리메틸-2-옥소-3,4-디히드로-1h-퀴녹살린-7-일)페녹시]에틸옥시 화합물 또는 그의 염
TW201927769A (zh) 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉｉ
MX2020006348A (es) * 2017-12-18 2020-09-03 Gruenenthal Gmbh Pirrolidinamidas i sustituidas.

Also Published As

Publication number Publication date
EP3908581A1 (en) 2021-11-17
AU2020207591A1 (en) 2021-09-02
KR20210114972A (ko) 2021-09-24
PE20211733A1 (es) 2021-09-06
TWI827785B (zh) 2024-01-01
US20200223840A1 (en) 2020-07-16
CA3125929A1 (en) 2020-07-16
CO2021008998A2 (es) 2021-07-30
CL2021001823A1 (es) 2022-02-04
JP2022516785A (ja) 2022-03-02
WO2020144375A1 (en) 2020-07-16
JP7446316B2 (ja) 2024-03-08
IL284642A (en) 2021-08-31
US20220089573A1 (en) 2022-03-24
CN113382990A (zh) 2021-09-10
WO2020144375A9 (en) 2020-10-29
TW202043211A (zh) 2020-12-01
MX2021008364A (es) 2021-08-05
BR112021013557A2 (pt) 2021-09-21

Similar Documents

Publication Publication Date Title
ECSP21051067A (es) Amidas de pirrolidina III sustituidas
ECSP18060342A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
CO2018004968A2 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
MX2020006355A (es) Pirrolidinamidas ii sustituidas.
CO2018011105A2 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj)
ECSP21003718A (es) Derivados de triazolquinoxalina adicionalmente sustituidos
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
PH12019550155A1 (en) ARYL HYDROCARBON RECEPTOR (AhR) MODULATOR COMPOUNDS
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
CR20190392A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CO2019007882A2 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
MX2021000762A (es) Derivados de triazoloquinoxalina sustituida.
MX2017016054A (es) Proceso para la preparacion de apremilast y sus intermedios.
CO2023007404A2 (es) Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
MX2020006348A (es) Pirrolidinamidas i sustituidas.
MX2020004536A (es) Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka).
MX2019003175A (es) Aminas ciclicas de 6 miembros o lactamas sustituidas con urea y fenilo.
WO2020254552A3 (en) Substituted pyrrolidine amides v
MX2019000006A (es) Composiciones para el tratamiento de estrias y ulceras de origen isquemico.
EA202191879A1 (ru) Замещенные амиды пирролидина iii